Compare Crispr Therapeutics AG (CRSP) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Docusign Inc — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while Docusign Inc trades at $58.51 (market cap $11.33B). The key difference: Docusign Inc is far larger — about 2.2× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | DOCU | |
|---|---|---|
Market Cap | $5.23B | $11.33B |
Sector | Health | Technology |
52-Week High | $76.78 | $85.01 |
52-Week Low | $44.34 | $41.75 |
Enterprise Value | $3.65B | $10.70B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
